Brain Tumor Committee

Committee Charge

The NRG Brain Tumor Committee’s charge is to pursue clinical research to better the survival and survivorship of patients with primary and secondary tumors of the central nervous system. Their focus areas are metastatic disease to the central nervous system, primary glial tumors, and additional brain neoplasms such as meningioma, primary central nervous system lymphoma, and others.  Our primary research priorities are to identify strategies to improve survival, maintain quality of life and cognitive function, investigate and provide optional palliative strategies, test and evaluate novel targeted and therapeutic strategies, and pursue combinatorial therapies. Overarching goals of the committee include: identifying the best approaches to manage brain metastases; identifying approaches to lengthen survival for patients with malignant glioma; identifying and ameliorating factors responsible for toxicities, cognitive decline, and reduction in quality of life for patient with longer survival; and, identifying the best approaches to maximize local control and enhance cure for locally recurrent tumors. This committee meets monthly via teleconference and in-person at the NRG Semiannual Meetings.